These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7449936)

  • 1. Failure of carbidopa and L-dopa to suppress the prolactin stimulating effect of sulpiride in normal man.
    Zanoboni A; Zanoboni-Muciaccia W; Gattei G; Crespi R
    Farmaco Prat; 1980 Oct; 35(10):510-5. PubMed ID: 7449936
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
    Jones MK; Ramsay ID; Jenner PG
    Br J Clin Pharmacol; 1978 May; 5(5):425-30. PubMed ID: 656281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.
    Szabo M; Nakawatase C; Kovathana N; Frohman LA
    Neuroendocrinology; 1977; 24(1):24-34. PubMed ID: 600362
    [No Abstract]   [Full Text] [Related]  

  • 5. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sulpiride and L-dopa on anterior pituitary hormones in plasma of normal men and women.
    Zanoboni A; Zanoboni-Muciaccia W; Zanussi C
    Farmaco Prat; 1979 Feb; 34(2):71-84. PubMed ID: 456543
    [No Abstract]   [Full Text] [Related]  

  • 7. L-3,4-dihydroxyphenylalanine (L-dopa) as an inhibitor of prolactin release.
    Jimenez AE; Voogt JL; Carr LA
    Endocrinology; 1978 Jan; 102(1):166-74. PubMed ID: 743945
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ineffectiveness of L-DOPA on hyperprolactinemia induced with sulpiride].
    Barreca T; Rolandi E; Masturzo P; Gianrossi R; Cicchetti V
    Boll Soc Ital Biol Sper; 1975 Jun; 51(12):755-8. PubMed ID: 1222098
    [No Abstract]   [Full Text] [Related]  

  • 9. [Plasma prolactin and GH response after thyrotropin-releasing hormone (TRH), L-DOPA and sulpiride in patients with senile dementia of Alzheimer type].
    Fujita M; Toyoda K; Motomura N; Kuroda K; Shimizu T
    Rinsho Shinkeigaku; 1985 Jul; 25(7):767-75. PubMed ID: 3935351
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels.
    Ogawa A; Kanazawa M; Takayanagi M; Kitani Y; Shintaku H; Kohno Y
    Brain Dev; 2008 Jan; 30(1):82-5. PubMed ID: 17590551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence on the direct action of L-Dopa on prolactin release.
    Donoso AO; Banzán AM; Barcaglioni JC
    Neuroendocrinology; 1974; 15(3-4):236-9. PubMed ID: 4420786
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention with sulpiride of the inhibitory effect of L-DOPA on prolactin secretion].
    Rolandi E; Barreca T; Masturzo P; Polleri A
    Boll Soc Ital Biol Sper; 1975 Jun; 51(12):751-4. PubMed ID: 1222097
    [No Abstract]   [Full Text] [Related]  

  • 13. Abnormalities in the regulation of prolactin in patients on maintenance hemodialysis.
    Leu ML; Huang HS; Huang BY; Huang CC
    Taiwan Yi Xue Hui Za Zhi; 1985 Sep; 84(9):1059-70. PubMed ID: 3937888
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
    Nurzia A; Vacca U; Pirro R; Cerone G
    Clin Ter; 1975 Aug; 74(3):265-70. PubMed ID: 1227747
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission.
    Corenblum B; Shaffer EA
    Horm Metab Res; 1989 Dec; 21(12):675-7. PubMed ID: 2559014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of peripheral adrenoreceptors and vasopressin in the suppression of plasma renin activity by L-dopa in carbidopa-treated dogs.
    Blair ML; Reid IA; Keil LC; Ganong WF
    J Pharmacol Exp Ther; 1979 Sep; 210(3):368-72. PubMed ID: 480187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia.
    Kelley SR; Kamal TJ; Molitch ME
    Am J Physiol; 1996 Jan; 270(1 Pt 1):E96-100. PubMed ID: 8772480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
    Goshima Y; Nakamura S; Misu Y
    J Pharmacol Exp Ther; 1991 Aug; 258(2):466-71. PubMed ID: 1865350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of sulpiride-induced prolactin secretion by dihydroergocristine in man.
    Poli M; Caviezel F; Girardi AM; Bosi E; Pozza G
    Adv Biochem Psychopharmacol; 1980; 24():445-9. PubMed ID: 6773304
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
    Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
    Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.